Dermapharm Holding SE (FRA:DMP) Beta: 0.3433 (As of Jun. 26, 2026)


FRA:DMP Dermapharm Holding SE FRA:DMP
87 GF Score
Price €46.25
GF Value €39.11
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Dermapharm Holding SE Beta?

Dermapharm Holding SE FRA:DMP -0.64% 87 Beta is 0.3433 as of Jun. 26, 2026. GuruFocus rates FRA:DMP with a GF Score™ of 87/100 and a GF Value™ of €39.11 (Modestly Overvalued). The stock has 9 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Dermapharm Holding SE's Beta is 0.3433.


Dermapharm Holding SE  (FRA:DMP) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Dermapharm Holding SE Beta Related Terms


Dermapharm Holding SE Beta Historical Data

* Premium members only.

The historical data trend for Dermapharm Holding SE's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dermapharm Holding SE Beta Chart

Dermapharm Holding SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.97 1.23 1.29 1.04 -0.38

Dermapharm Holding SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 1.01 0.40 -0.38 0.02

FRA:DMP vs ZTS, UTHR, VTRS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermapharm Holding SE Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Beta distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's Beta falls into.


FRA:DMP
87GF Score
Dermapharm Holding SE FRA:DMP
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dermapharm Holding SE Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.3433 mean?
Dermapharm Holding SE (FRA:DMP) has a Beta of 0.3433 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Dermapharm Holding SE and its competitors.
Is Dermapharm Holding SE's Beta too high?
Dermapharm Holding SE's current Beta is 0.3433. Overall, Dermapharm Holding SE has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Beta compare to ZTS and UTHR?
Dermapharm Holding SE's Beta of 0.3433 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Dermapharm Holding SE and its competitors. Dermapharm Holding SE's current Beta is 0.3433. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Based on GuruFocus' analysis, Dermapharm Holding SE (FRA:DMP) is currently considered Modestly Overvalued. The stock's GF Value™ is €39.11, compared to a current price of €46.25 — trading 18.3% above its estimated fair value. The current Beta is 0.3433. Dermapharm Holding SE's overall GF Score™ is 87/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Dermapharm Holding SE (FRA:DMP), the current Beta is 0.3433 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dermapharm Holding SE (FRA:DMP) Overvalued in 2026?

Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued. The current stock price of €46.25 is trading 18.3% above its estimated GF Value™ of €39.11. GuruFocus considers Dermapharm Holding SE to be Modestly Overvalued.

Key valuation signals for FRA:DMP:

  • Beta: 0.3433
  • GF Value™: €39.11 vs. price of €46.25 (18.3% above fair value)
  • GF Score™: 87/100 with 9 warning signs

No single metric tells the full story. See the FRA:DMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dermapharm Holding SE Business Description

Address Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
87GF Score

Get the complete analysis for FRA:DMP

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.25
Price
€39.11
GF Value